{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006034","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.095563+00:00","generated_at":"2026-05-30T04:57:46.561432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)","bullets":["Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.","Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.","Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.","FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.","GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006034","json":"https://secwatch.observer/filing/0001171843-24-006034.json","markdown":"https://secwatch.observer/filing/0001171843-24-006034.md","text":"https://secwatch.observer/filing/0001171843-24-006034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/0001171843-24-006034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/f8k_110624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:57:46.561432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}